noom glp-1 companion program Retention, Renewal, Results: Noom's GLP‑1 Noom Launches Microdose GLP-1 Program,

Listen to this episode of Longevity by Design on Apple Podcasts, Spotify, and Google Podcasts GLP-1 agonist medications have been a popular topic of discussion recently

Persistent tiredness could indicate that your body isn't adjusting as anticipated and may necessitate adjusting your dosage or a change in treatment plan

The trial found that after 5 years, Wegovy significantly reduced the risk of death from heart disease by 15% and reduced the risk of cardiovascular events including nonfatal heart attacks and strokes by 20%, compared to an inactive placebo

Min SH, Yoon JH, Moon SJ, Hahn S, Cho YM (2018) Combination of sodium-glucose cotransporter 2 inhibitor and dipeptidyl peptidase-4 inhibitor in type 2 diabetes: a systematic review with meta-analysis

Los resultados indican que la gentica tiene un papel, aunque limitado, en la respuesta a estos frmacos